Sector: Health Care
Director information for ZEVRA THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Adrian Quartel, M.D., FFPM | Chief Medical Officer | 59 | ["Chief Medical Officer of Acer Therapeutics","Chief Medical Officer at Zevra","Chief Medical Officer at Adamas Pharmaceuticals","Group Vice President of Global Medical Affairs at BioMarin Pharmaceuticals Inc.","clinical development and senior medical leadership positions at Astellas, Chiltern, and ICON Clinical Research","clinical research fellow at UCLA Cedars-Sinai","resident in cardio-thoracic surgery at Erasmus University Medical Center","M.D. from Erasmus University Medical School, Rotterdam","postgraduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London","board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom"] | [] | 2026 |
| Alicia Secor | Director; President and Chief Executive Officer | 63 | ["More than 30 years of experience in the life sciences industry","CEO and director of private and public companies"] | ["l","Audit","Compensation"] | 2026 |
| Alvin Shih, M.D. | Director | 49 | ["Leadership experience in the biotechnology industry","Experience in rare disease","Chief operating officer and founding member of Pfizer Inc.’s rare disease research unit","CEO of Imbria Pharmaceuticals","CEO of Catamaran Bio, Inc.","CEO of Disarm Therapeutics","CEO of Enzyvant Therapeutics","Executive vice president and head of research at Retrophin, Inc.","Management consulting at McKinsey & Company and L.E.K. Consulting, LLC","M.D. from the University of Alabama","M.B.A. from the Kellogg School of Management at Northwestern University"] | ["l","Compensation","Nominating and Corporate Governance"] | 2026 |
| Corey Watton | Director | 56 | ["senior leadership roles in the medical services industry","expertise in accounting"] | ["l","Audit","Compensation"] | 2026 |
| Douglas W. Calder | Director | 59 | ["More than 30 years of life science executive experience","Served in various senior executive roles for Florida-based biotechnology companies and research institutes","Former registered financial portfolio manager focused on life science equities"] | ["l","Compensation","Nominating & Corporate Governance"] | 2026 |
| John Bode | Director | 51 | [] | [] | 2026 |
| Joshua Schafer | Chief Commercial Officer | 55 | ["Over 25 years of pharmaceutical commercial experience","New product development experience","Merger and acquisition experience","Former General Manager and Senior Vice President at Mallinckrodt Pharmaceuticals","Former Chief Strategy and Business Officer at Mallinckrodt Pharmaceuticals","Former Vice President and Oncology Therapeutic Area Head at Astellas Pharmaceuticals","Held senior roles at Takeda Pharmaceuticals, Accenture, G. D. Searle & Co., and Cognia Corporation","B.A. in Biology and German from the University of Notre Dame","M.S. in Biotechnology and M.B.A. from Northwestern University"] | [] | 2026 |
| Neil F. McFarlane | Director; President and Chief Executive Officer | 53 | ["over 25 years of global biopharmaceutical and life sciences experience","executive leadership","corporate governance","finance","operations","international","investor relations"] | [] | 2026 |
| Tamara A. Favorito | Board Chair; Chair of the Board | 67 | ["More than 35 years of life sciences industry experience","20 years as a chief financial officer","Experience in corporate management, finance and life science","Served as board member and audit committee chair of Artelo Biosciences","Experienced in leading multiple private and public financings and M&A transactions","Certified public accountant","MBA from Georgia State University","BBA from Valdosta State University"] | ["+","Audit"] | 2026 |
| Thomas D. Anderson | Director | 70 | ["35-year veteran of the biopharma industry","led high-growth organizations","former CEO of SwanBio Therapeutics","chief commercial strategy officer of Sage Therapeutics","senior executive with Shire Pharmaceuticals Group","17 years at Johnson & Johnson"] | ["Compensation","Nominating and Corporate Governance"] | 2026 |
